GSK (LON:GSK) Shares Cross Above Two Hundred Day Moving Average – What’s Next?

GSK plc (LON:GSK)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,562.34 and traded as high as GBX 1,824. GSK shares last traded at GBX 1,812.50, with a volume of 7,323,830 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Shore Capital reiterated a “buy” rating and set a GBX 2,100 target price on shares of GSK in a report on Monday, October 20th. JPMorgan Chase & Co. increased their price objective on GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a report on Friday, November 7th. Jefferies Financial Group raised their target price on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research note on Monday, November 3rd. Finally, Berenberg Bank boosted their target price on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of GBX 1,762.

GSK Price Performance

The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The company has a market capitalization of £72.96 billion, a P/E ratio of 13.59, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a 50 day moving average price of GBX 1,754.77 and a 200 day moving average price of GBX 1,562.34.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities analysts predict that GSK plc will post 175.980975 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.